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Edited by Bernard HelmsAbstract A link between alterations in cholesterol homeostasis
and Alzheimer’s disease (AD) is nowadays widely accepted.
However, the molecular mechanism/s underlying such link re-
main unclear. Numerous experimental evidences support the view
that changes in neuronal membrane cholesterol levels and/or sub-
cellular distribution determine the aberrant accumulation of the
amyloid peptide in the disease. Still, this view comes from rather
contradictory data supporting the existence of either high or low
brain cholesterol content. This is of particular concern consider-
ing that therapeutical strategies aimed to reduce cholesterol lev-
els are already being tested in humans. Here, we review the
molecular mechanisms proposed and discuss the perspectives
they open.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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What causes Alzheimer’s disease (AD), the most common
form of dementia aﬀecting up to 15 million individuals world-
wide? Although there is not yet an answer to this question the
search for it has provided a wealth of information that bring us
closer to the understanding of this neurodegenerative disorder.
Hence, its hystopathological hallmarks are well characterized:
amyloid plaques and neuroﬁbrillary tangles composed by the
extracellular and intracellular accumulation in the brain of
the amyloid peptide (Ab) and the hyperphosphorylated protein
Tau, respectively. Even though it is unclear whether these hall-
marks are a consequence or a cause their analysis has been cru-
cial towards the comprehension of the pathology. Thus, Ab
derives from the processing of the transmembrane amyloid
precursor protein (APP) by the b- and c-secretases [1]. Ab pro-
duction is a physiological event, and therefore it is necessary
for relevant cellular functions including modulation of synap-
tic activity and facilitation of neuronal growth and survival [2].
On the other hand, abnormal increase in Ab levels, even before
its accumulation in plaques, appears to be toxic in vitro and*Corresponding author. Fax: +3216330522.
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doi:10.1016/j.febslet.2006.06.038in vivo [3]. Consistent with this peptide playing a key patholog-
ical role in AD, mutations in either APP or its secretases are a
well established cause for the familial forms of the disease [4].
Being APP cleavage a membrane event the involvement of
lipids in alterations of such cleavage is conceivable. The ﬁrst
link between a lipid defect and AD came with the observation
that the inheritage of the e4 allele of the apolipoprotein E, the
main cholesterol transport protein in the brain, constituted a
risk factor for the disease [5]. Indeed, individuals who are homo-
zygous for this allele and live longer than 80 years will almost
invariably develop AD. Lately, genetic studies of the risk of
AD have reported association with polymorphisms in three
other cholesterol related genes: cholesterol 24-hydroxylase
(CYP46A1), ATP-binding cassette transporter A1 (ABCA1)
and lipoprotein receptor-related protein (LRP) [6]. In addition,
other evidences support an involvement of cholesterol in the
production and/or degradation of the amyloid peptide. How-
ever, no consensus arises on how defects in cholesterol homeo-
stasis relate to AD. The purpose of this article is to review the
data aimed at this understanding.2. Why the brain regulates tightly the levels of cholesterol?
Cholesterol is an essential component of the cellular mem-
branes determining the ﬂuidity and biophysical properties by
lowering the permeability and increasing the compacity. The
distribution of this lipid in the membrane is not uniform but
it is enriched in microdomains, the so-called rafts [7]. Numerous
experimental evidences suggest that by means of raft formation
cholesterol contributes to the dynamic compartmentalization of
molecules allowing the ﬁne-tuned modulation of events such as
signaling and proteolysis [8]. In addition, cholesterol serves as a
precursor or cofactor of several signaling molecules [9]. As the
main component of rafts cholesterol also contributes to the
sorting of certain membrane molecules to the right destination
in polarized cells such as epithelia and neurons [7,10,11] and to
raft molecule endocytosis [11,12]. More speciﬁcally, cholesterol
is crucial for themost distinctive feature of neurons: their ability
to communicate. First, it is required for the formation of syn-
apses [13]. Second, it is a major component of the myelin sheath
essential for an eﬃcient electrical transmission [14]. Third, it
serves as impermeant barrier against sodium leakage [15]. From
the above it comes that the brain must posses a most robust
mechanism to maintain the levels of cholesterol, in the neuronsblished by Elsevier B.V. All rights reserved.
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variations that occur in the circulation. In fact, to date there
is no evidence that blood cholesterol crosses the brain–blood
barrier [16].3. How are cholesterol levels regulated in the brain?
The metabolism of cholesterol depends on three main as-
pects: synthesis, transport and catabolism. Cholesterol biosyn-
thesis is a lengthy and energy consuming process that requires
more than 20 reactions and intermediates. Production of mev-
alonate by the HMG-CoA reductase is the main regulatory
step of the pathway. Developing neurons synthesize most of
the cholesterol they need but the production is reduced once
they reach maturation. At this point, neuronal cholesterol con-
tent becomes also dependent on the cholesterol synthesized
and secreted by glial cells [16]. The transport of cholesterol
among CNS cells appears to rely on the Apolipoprotein E that
is synthesized by astrocytes [17]. ApoE-cholesterol complexes
are then taken up by neurons via endocytosis through the
LDL receptor related protein (LRP1) [18]. Assuming that the
following step is conserved with that of other cells, endocyto-
sed cholesterol-containing lipoproteins are hydrolyzed in the
neuronal lysosomes allowing the intracellular release of free
cholesterol. This can be utilized in two ways. On one hand,
it is esteriﬁed in the endoplasmic reticulum by the acyl-coen-
zyme A cholesterol acyltransferase (ACAT), and stored in
cytoplasmic droplets as a reserve pool [19]. On the other hand,
free cholesterol provides feedback to the pathways regulating
transcription factors that control the expression of cholesterol
synthesizing enzymes and lipoprotein receptors. Examples of
these are the sterol regulatory element-binding protein [20]
or liver X receptors (LXRs). The later have been shown to en-
hance the release of cholesterol from cultured astrocytes and
neurons by increasing the expression of the ATP-binding cas-
sette transporter A1 (ABCA1) [21], a member of the family of
ABC transporters, which mediates the transport of cholesterol
from cells to Apolipoproteins, closing the cellular cycle of the
lipid.
The fact that the neuronal membranes must be kept with a
fairly constant amount of cholesterol, so to guarantee proper
function, implies the existence of a mechanism for cholesterol
removal. Because there is no degradation mechanism for this
lipid any excess must exit the brain into the circulation.
Hydroxylation of the side chain of cholesterol by the choles-
terol 24-hydroxylase allows the sterol molecule to cross the
blood–brain barrier freely [15]. This mechanism is responsible
for the catabolism of most of the cholesterol that is turned over
in the brain.4. Is hypercholesterolemia a risk factor for AD because of higher
cholesterol reaching the brain?
The striking reduction (almost 70%) in the prevalence of AD
found in hypercholesterolemic patients treated with the choles-
terol lowering drugs statins [22,23] led to establish the correla-
tions ‘‘high circulating cholesterol-predisposition to AD’’ and
its counterpart ‘‘cholesterol lowering drugs-reduced AD risk’’.
This was further supported by studies in animals showing thathigh dietary cholesterol results in increased levels of Ab and
that treatment with cholesterol synthesis inhibitors leads to re-
duced amounts of Ab40 and Ab42 [24,25]. Mechanistically
speaking the human and animal data can be explained in
two diﬀerent ways. The ﬁrst is that high circulating cholesterol
reaches the brain triggering neuronal dysfunction. The second
is that neuronal dysfunction is the consequence of the numer-
ous collateral defects that arise because of high blood choles-
terol, most notably perturbed circulation and thus tissue
oxygenation, without changes in the brain levels of this lipid.
To distinguish between these possibilities it would be necessary
to address certain issues. Most relevant is to know whether or
not hypercholesterolemic individuals have more cholesterol in
their brains than age-matched control individuals. Intuitively,
this is not likely as brain cholesterol levels are controlled lo-
cally independently from the oscillations in peripheral choles-
terol (see above). In agreement, high cholesterol diets or
statin treatments in the experimental animals failed to change
brain cholesterol levels signiﬁcantly [26]. Although it could be
argued that hypercholesterolemic individuals have, as conse-
quence of this defect, a perturbation of the normal choles-
terol-impermeant function of the blood–brain barrier, this
possibility is also unlikely, as a permeability defect would lead
to the leakage into the brain of blood components, not only
cholesterol, producing rather acute syndromes but not AD.
From the above data and considerations one would have to
conclude that there is no ground to think that hypercholester-
olemia predisposes to AD because of the passage of circulating
cholesterol to the brain making neurons ‘‘fatter’’. If this is ac-
cepted it then comes that hypercholesterolemia may lead to
AD through a secondary event, most likely the poor-oxygena-
tion of the brain due to cholesterol-clogged blood vessels. This
would be consistent with the observation that people who had
suﬀered brain trauma are also more prone to develop the dis-
ease [27]. Utilizing the same rationale, statins would not pre-
vent or delay (if at all the case) the occurrence of the disease
because of inhibiting cholesterol synthesis in brain cells or be-
cause of reducing the amount of peripheral cholesterol reach-
ing the brain, but because of the overall improvement of
circulation. Statins could also be beneﬁcial because of their
anti-inﬂammatory actions [28]. Considering all the above,
and in following with the title of this review, high circulating
cholesterol is not to be blamed for AD through a direct eﬀect
on the brain. Certainly, this does not rule out that changes in
the content or distribution of cholesterol in neurons, by mech-
anism/s other than high circulating levels, occur in AD and are
responsible for high amyloid production.5. How does the e4 allele of the apolipoprotein E predispose to
AD?
The only established molecular event directly linking choles-
terol metabolism and AD comes from the discovery that the e4
allele of the ApoE predisposes to the disease [5]. The view that
ApoE would contribute to AD by aﬀecting Ab levels came
from the ﬁndings that mice lacking ApoE present reduced
deposition of Ab [29] whereas the expression of apoE3 and
ApoE4 in a mouse model for AD resulted in higher accumula-
tion of ﬁbrilar Ab substantially more abundant in the later
[30]. While the early work did not make any assumption that
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brain cholesterol, this was later thought to be the case because
apoE4-bearing individuals have high circulating cholesterol
and hypercholesterolemia increases the risk for AD [31]. The
same question asked in regard to the hyper-cholesterolemic hu-
man/animal models, applies therefore to the ApoE4 genetic
correlation: do ApoE4 bearing people have increased brain
cholesterol levels? The same arguments against this possibility
utilized for the nonApoE4 hypercholesterolemic individuals
apply here as well. Moreover, biochemical data from the hip-
pocampal membranes of a few ApoE4-bearing AD patients
indicate not only that there is no such increase in cholesterol
but, on the contrary, that there is a moderate decrease [32].
While this is surprising if one takes the view that high circulat-
ing cholesterol will result in high neuronal cholesterol, it is pre-
dictable if one considers that ApoE4-derived glial cells have
low ability to release cholesterol [33]. As described earlier, ma-
ture neurons are dependent on the cholesterol provided by glial
cells.
The existing data make unlikely that ApoE4 predisposes to
AD because of higher neuronal cholesterol content due to
hypercholesterolemia. While it is beyond the scope of this re-
view, we will brieﬂy summarize below data on how the pres-
ence of ApoE4 can predispose to the disease in a high
circulating cholesterol- independent manner. One possibility
would be through the ability of ApoE to bind with high aﬃnity
to Ab [34], thus acting as a scavenger for the extracellular pep-
tide [35]. This mechanism could be less eﬃcient for the E4 al-
lele. This role would rely on the binding of Ab-ApoE to the
ApoE receptor LRP facilitating Ab endocytosis and degrada-
tion [36]. Alternative mechanisms for the involvement of ApoE
in AD derive from its roles in brain repair [37], regulation of
antioxidative processes [38] or increased intracellular signaling
of calcium in neurons [39].
Future work will determine whether a diﬀerent modulation
of neuronal cholesterol levels and transport by the diverse
ApoE isoforms could participate in AD pathology. In line with
this possibility a number of recent evidences suggest that
changes in neuronal cholesterol, whether in its total content,
free or steriﬁed, or in its subcellular distribution can be blamed
for high amyloid production. These results are discussed next.6. Is high neuronal cholesterol responsible for high amyloid
production?
In an early work Simons and colleagues showed that reduc-
tion of cholesterol from the plasma membrane of cultured APP
overexpressing rat hippocampal neurons, through the addition
of a cholesterol-synthesis inhibitor (statin) and a cholesterol-
extracting drug (cyclodextrin), resulted in the drastic reduction
of amyloid production [40]. This work was expanded by that of
Ehehalt and coworkers who pointed to the critical involvement
of cholesterol within lipid rafts. Thus, these authors showed,
utilizing antibodies against APP and its b-secretase BACE in
overexpressing neuroblastoma cells, that the two proteins co-
cluster in such domains and that cholesterol reduction, upon
statin and cyclodextrin treatments, diminished the amount of
Ab [41]. Because Ehehalt and colleagues also found that Ab
production was dependent on the expression of endocytic mol-
ecules, such as dynamin and Rab5, it was proposed a modelfor APP processing in which the small size and the dispersion
of rafts at the cell surface maintain APP and BACE segregated
in diﬀerent rafts. Upon endocytosis raft co-cluster and APP
and BACE1 will encounter thus favoring b-cleavage. In such
scenario APP would be cleaved by raft BACE 1. Following
with these authors’ model, anomalous high levels of choles-
terol in the brains would enhance raft co-clustering leading
to higher Ab production. In agreement, the expression of a
GPI form of BACE capable of directing this protein to rafts,
results in increased Ab production in an APP overexpressing
neuroblastoma cell line [42]. The signiﬁcance of these results,
which derive from over-expression of APP and BACE in
undiﬀerentiated cells, became challenged by work in cultured
primary hippocampal neurons expressing constitutive levels
of these proteins [43]. In this study it was shown that BACE
is in rafts but not APP. In these cells a moderate reduction
of cholesterol results in the enhancement of APP-b-cleavage
and Ab production not in its inhibition. From all these data
two opposite models arise. In one, neurons of AD patients
have some sort of defect, genetic or environmental, that makes
them possess high plasma membrane cholesterol and clustered
rafts. This results in increased raft BACE-mediated APP cleav-
age leaving this molecule ready for the action of the c-secretase
for Ab generation. In the other, AD arises as a consequence of
the opposite event, loss of neuronal cholesterol from rafts be-
cause of unknown intrinsic or extrinsic causes. This leads to
the ‘‘escape’’ of BACE from the raft domains to non-raft ter-
ritories where APP resides, therefore increasing cleavage.
Although more work is needed to clarify which model is closer
to reality some recent data have provided important cues.
Thus, the analysis of brain membrane cholesterol content in
a number of AD patients and control individuals revealed that
the former present a moderate, still signiﬁcant, reduction of
cholesterol in areas particularly loaded with amyloid plaques
[32]. This resulted in the ineﬃcient activation of the amyloid
degrading enzyme plasmin, which is a raft dependent event,
in such brains. Moreover, when similar level of cholesterol
reduction was achieved in cultured hippocampal neurons the
plasmin deﬁcit was also observed [32]. In the same line,
Abad-Rodriguez and colleagues showed that the hippocampal
membranes of AD patients with reduced cholesterol content
present disorganized rafts with enhanced BACE and APP
colocalization in non-raft membrane domains. These results,
which would support that low membrane cholesterol induces
increased Ab production in AD, are in agreement with the
observation that seladin 1, the enzyme responsible for the last
step of cholesterol synthesis, is speciﬁcally downregulated in
aﬀected areas of AD brains [44]. Moreover, mice lacking one
allele of seladin 1, which show similar reduction of brain mem-
brane cholesterol than that reported in the AD patients, pres-
ent raft disorganization, low plasmin activity and increased
APP-b-cleavage and Ab levels [45].7. Is it changes in the intracellular distribution of cholesterol,
rather than its absolute levels, that aﬀect Ab production?
As described earlier cellular cholesterol is present either as
free cholesterol in the membrane or stored as cholesteryl-esters
in the form of cytoplasmic droplets. It is thought that choles-
terol-esters in cytoplasmic droplets serve storage and synthesis-
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cholesterol becomes reduced, replenishment is achieved
through droplet mobilization and activation of the synthesis
machinery. The importance of cholesterol ester content in
the control of Ab levels was suggested by the study of PuglielliRAFTS NON
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the reduction in cholesterol esteriﬁcation induced by ACAT
inhibition leads to higher levels of free cholesterol in the mem-
brane and since Ab is generated in membranes that contain
free cholesterol, it could be argued that cholesterol esters reg-
ulate Ab production by modulating the amount of free mem-
brane cholesterol. Work is needed to verify this prediction.
Moreover, to give clinical relevance to these data it would be
important to know whether or not neurons from AD patients
have altered ACAT enzymatic activity, in gain or loss mode, or
anomalous cholesterol ester amounts.
Another possible abnormality of brain cholesterol that could
lead to AD is in situations of defective transport. In this re-
gard, Runz and coworkers reported that drugs that arrest cho-
lesterol traﬃcking in late endosomal/lysosomal compartments
result in increased APP c-cleavage activity and Ab levels [47].
Since under such conditions presenilins accumulate in Rab7
positive vesicular compartments these authors proposed a
model in which altered cholesterol distribution, increased in
the late endocytic pathway, modiﬁes secretase localization thus
aﬀecting Ab production. Support for this model derives from
the increased levels of Ab and enhanced c-secretase activity
observed in mice lacking NPC1 [48], a transmembrane protein
involved in the egress of unesteriﬁed cholesterol from late
endosomes/lysosomes, which deﬁcit cause the Niemann Pick
disease type C (NPC). However, the fact that, diﬀerent from
AD, neurodegeneration in NPC occurs in early life makes un-plasmin
plasminogen
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Amyloid
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APP
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Fig. 2. Low neuronal membrane cholesterol model for AD. In a control situ
non raft membranes of neurons. This segregation keeps the production of
membrane and activation to the amyloid degrading enzyme plasmin occurs
maintenance of non deleterious steady state levels of Ab. In contrast, raft dom
cholesterol. This favors the interaction of BACE1 and APP in non-raft memb
binding to the membrane and activation to plasmin is impaired due to raft di
to its aberrant accumulation. The reduced ability of ApoE4 astrocytes to pro
contribute to the low amounts of membrane cholesterol in AD brains.likely that the same defect is to be blamed for both diseases.
Alternatively, the extent of such defect would determine the
onset and type of pathology.
Finally, changes in the asymmetric distribution of choles-
terol in the exofacial and cytoplasmic leaﬂets of the mem-
branes can be the cause of an abnormal ‘‘gain’’ in membrane
cholesterol content, leading to increased Ab production [26].
In this regard, ApoE4 knock-in mice show a twofold increase
in exofacial leaﬂet cholesterol of synaptic plasma membranes
compared with apoE3 knock-in mice and wild-type mice
[49]. These results would be consistent with the view that high
plasma membrane cholesterol in neurons could be a cause of
AD but in contradiction with the work showing a reduced abil-
ity of ApoE4 glia to provide neurons with cholesterol.8. Considerations about the conﬂictive results and many more
open questions
The data on cholesterol and AD here summarized can be
divided into two, well separated, aspects. The ﬁrst aspect
concerns how high blood cholesterol predisposes to AD. If
it were not for the later appearance of data supporting the
notion that high cholesterol in neurons increases amyloid
production, the clinical correlation between hypercholesterol-
emic patients treated with statins and reduced risk to suﬀer
the disease, would have been taken as an indication that highplasminogen
plasmin
BACE1-APP
Amyloid
degradation
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production
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ation the major pool of BACE1 is in rafts while its substrate APP is in
Ab at physiological levels. In addition, plasminogen binding to the
in rafts. This contributes to the degradation of the peptide and the
ain disorganization occurs in AD brains due to low levels of membrane
ranes leading to increased amyloid production. Moreover, plasminogen
sorganization. This renders ineﬃcient the clearance of Ab contributing
vide with cholesterol to neurons compared to ApoE3 astrocytes would
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ily from poor circulation. However, the in vitro data in pseu-
do-neuronal and neuronal cells led many researchers to think
that high blood cholesterol individuals would have higher Ab
neuronal production because of increased brain levels of this
lipid. This conclusion appears today weak. In fact, the liter-
ature is rich in demonstrating that peripheral cholesterol
does not enter the CNS. Secondly, high brain cholesterol
due to brain barrier leakage is as well unlikely as hypercho-
lesterolemic patients do not present the symptoms of brain
barrier permeability defects. Thus, a most reasonable expla-
nation for why hypercholesterolemia predisposes to AD re-
mains the indirect pathway, consequence of a deﬁcient
brain oxygenation secondary to vessel obstruction. This indi-
rect mechanism would also explain why cholesterol synthesis
inhibitors such as statins are a good strategy for the preven-
tion of the brain side eﬀects of high circulating cholesterol.
Indeed, the potential beneﬁcial eﬀects of this type of drugs
were seen for both brain–blood barrier permeable and non-
permeable statins [26].
The second aspect concerns how cholesterol modulates Ab
production in neurons, irrespective of circulating cholesterol
levels. This, for the time being, is an issue more interesting
to the basic neurobiology community than to clinicians as
most of the data derive from cell biological/biochemical ap-RAFTS NON RAFTS
Amyloid
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Fig. 3. Altered cholesterol transport and/or storage model for AD. In a contr
hydrolyzed in the late endosome/lysosome compartments of neurons. Free
recycled to form the cellular membranes or converted to cholesterol esters
distribution of APP secretases is not completely elucidated, it seems that the
pool of presenilin is in the ER. This distribution of secretases and cholesterol
levels of cholesterol esters correlate with increased Ab production and low
could be that low membrane cholesterol due to high cholesterol esteriﬁcation
in anomalous high Ab levels. An alternative mechanism proposes the blockag
(depicted in the black box). This blockage leads to the accumulation of chole
presenilin in Rab7 positive vesicles nearby late endosomes/lysosomes. The
increased Ab production.proaches with very little correlation to the human scenario.
These data consistently show however, that cholesterol does
indeed play a role in Ab production. This is of no surprise
as Ab generation is a membrane associated event and choles-
terol a main membrane lipid. A prevalent view arising from
these results, enthusiastically supported by the defenders of
the hypercholesterolemia-AD predisposition, is that high neu-
ronal cholesterol enhances Ab production. A main drawback
of this conclusion is that a large body, if not all, of the
in vitro work supporting it (e.g. BACE-APP colocalization
in rafts and diminished Ab production upon cholesterol reduc-
tion) arises from cells overexpressing APP and/or its secretases.
It is known that changes in protein distribution induced by
over-expression occur in many cell types being especially evi-
dent in neurons, which have very tight axonal-dendritic sorting
machinery. In fact, studies on APP membrane distribution in
primary hippocampal neurons and human brains, under
endogenous levels of expression, failed to ﬁnd this protein
within rafts. A second drawback of linking high cholesterol
with high amyloid production is that the results supporting
this view derive from cells with normal cholesterol levels in-
duced to loose this lipid reaching concentrations far below
physiological. The opposite type of approach aimed at increas-
ing the levels of membrane cholesterol would have been more
appropriate than its reduction. However, when such ‘‘gain ofBACE1-APP
Amyloid
production
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cholesterol traﬃcs then to the endoplasmic reticulum where it can be
by ACAT to be stored in lipid droplets. Although the steady state
major pool of BACE1 resides at the plasma membrane while the major
results in the production of physiological levels of Ab. In contrast, high
free cholesterol in the cellular membranes. A possible scenario in AD
impairs BACE1-APP segregation through raft disruption. This results
e of cholesterol transport from late endosome/lysosomal compartments
sterol in these organelles and to the redistribution of the major pool of
change in the intracellular localization of presenilin would lead to
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expected one: decreased amyloid production [45]. In any event,
even if controversial, the data linking cholesterol, Ab levels
and AD contributed to the idea that this disease may be, in
its roots, the consequence of a basic membrane defect. In this
view, an alteration in cholesterol levels, in more or less, would
be suﬃcient to induce changes in membrane proteins’ com-
partmentalization, aﬀecting the normal segregation of APP
and its secretases. Figs. 1 and 2 show how enhanced Ab gener-
ation could be accomplished in situations of ‘‘gain’’ or ‘‘loss’’
of membrane cholesterol. On the other hand, the recent evi-
dences that transport and/or storage defects of cholesterol
can lead to changes in the subcellular compartments where
APP and its secretases mainly reside, introduce new possible
ways by which excessive amyloid production can occur
(Fig. 3). In addition, these data open new perspectives of ther-
apeutical targets for the cure or at least amelioration of the
symptoms of the disease. In this regard, promising results have
been recently obtained with an inhibitor of the cholesterol-es-
ter forming enzyme ACAT, which markedly reduces amyloid
pathology in a mouse model of AD [50].
Although most of the mechanisms proposed for the
involvement of cholesterol point to a causative role in Ab
accumulation, recent work has demonstrated the ability of
the peptide to regulate the synthesis of this lipid through
the inhibition of HMGR [51]. Moreover, Ab has the capacity
to sequester cholesterol from the membrane [52]. These evi-
dences raise the question on whether cholesterol alterations
are a cause or a consequence in the disease. Indeed, the stud-
ies on cholesterol and AD bring about more questions than
answers. For instance, if changes in the membrane ﬂuidity
are to be blamed for the link between cholesterol and altera-
tions in Ab generation/degradation, what role do other major
lipids of the membrane play? In particular, and considering
the postulated relevance of raft domains, could alterations
in the raft-enriched sphingomyelin have the same eﬀects? If
rafts are altered, what are the consequences for other raft-
mediated functions such as signaling or sorting of molecules?
Defects in which of these produce the signs and symptoms of
the disease? Given the relevance of cholesterol in synapse for-
mation, could alterations in this lipid be responsible for the
prominent synaptic loss in AD brains? And at the base of
all these questions what is the cause for membrane choles-
terol alterations in AD? Work on the above issues will cer-
tainly contribute to better understand the reasons behind
this devastating disorder.
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